bCentro INFANT de Medicina Traslacional (CIMeT), Escuela de Bio y Nanotecnología, Universidad Nacional de San Martín (UNSAM), Buenos Aires, Argentina cConsejo Nacional de Investigaciones Científicas y ...
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...
Background The pathogenesis of multiple sclerosis (MS) requires both genetic factors and environmental events. The question remains, however, whether these factors and events completely describe the ...